Literature DB >> 16266204

Eprosartan: a review of its use in the management of hypertension.

Gayle W Robins1, Lesley J Scott.   

Abstract

The angiotensin II receptor antagonist eprosartan is approved for the treatment of essential hypertension and may be administered using a convenient once-daily regimen. The drug is a well tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, independent of blood pressure (BP)-lowering effects. Eprosartan has a low potential for serious adverse events and has not been associated with clinically significant drug interactions, establishing it as a promising agent for combination antihypertensive strategies. Unlike ACE inhibitors such as enalapril, eprosartan does not have a tendency to cause persistent nonproductive cough. Accordingly, eprosartan represents a useful therapeutic option in the management of patients with hypertension, including those who have had a stroke and those with co-morbid type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16266204     DOI: 10.2165/00003495-200565160-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  72 in total

1.  JNC 7--it's more than high blood pressure.

Authors:  Thomas E Kottke; Robert J Stroebel; Rebecca S Hoffman
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.

Authors:  D Tenero; D Martin; M Chapelsky; B Ilson; S Boike; S Patterson; J Keogh; S Rodriguez; D Jorkasky
Journal:  Pharmacotherapy       Date:  1998 Jan-Feb       Impact factor: 4.705

4.  The effect of treatment with eprosartan on pulse pressure: factors predicting response.

Authors:  Alejandro de la Sierra; Anna Muñoz; Emma Arcos; Juan Salvador López; Jordi Relats
Journal:  Can J Cardiol       Date:  2004-10       Impact factor: 5.223

5.  Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan.

Authors:  J C Balt; M J Mathy; M Pfaffendorf; P A van Zwieten
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

6.  The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.

Authors:  T Hedner; A Himmelmann
Journal:  J Hypertens       Date:  1999-01       Impact factor: 4.844

Review 7.  Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.

Authors:  D P Brooks; E H Ohlstein; R R Ruffolo
Journal:  Am Heart J       Date:  1999-09       Impact factor: 4.749

8.  Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.

Authors:  E Breeze; E C Rake; M D Donoghue; A E Fletcher
Journal:  J Hum Hypertens       Date:  2001-12       Impact factor: 3.012

9.  Characterization of renal angiotensin II receptors using subtype selective antagonists.

Authors:  R M Edwards; E J Stack; E F Weidley; N Aiyar; R M Keenan; D T Hill; J Weinstock
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

10.  Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan.

Authors:  Alexander Nap; Marie-Jeanne Mathy; Jippe C Balt; Martin Pfaffendorf; Pieter A van Zwieten
Journal:  Eur J Pharmacol       Date:  2003-05-23       Impact factor: 4.432

View more
  5 in total

1.  Formulation and statistical optimization of self-microemulsifying drug delivery system of eprosartan mesylate for improvement of oral bioavailability.

Authors:  Pankaj Dangre; Ritu Gilhotra; Shashikant Dhole
Journal:  Drug Deliv Transl Res       Date:  2016-10       Impact factor: 4.617

Review 2.  Eprosartan: a review of its use in hypertension.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Effects of eprosartan on target organ protection.

Authors:  Alejandro de la Sierra
Journal:  Vasc Health Risk Manag       Date:  2006

Review 4.  Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Authors:  P J Blankestijn; H Rupp
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10

5.  Effects of eprosartan on serum metabolic parameters in patients with essential hypertension.

Authors:  Evangelos C Rizos; Athanasia Spyrou; Evangelos N Liberopoulos; Eleni C Papavasiliou; Vasilis Saougos; Alexandros D Tselepis; Moses Elisaf
Journal:  Open Cardiovasc Med J       Date:  2007-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.